WorldHeart Announces Levacor VAD Clinical Results and Related Technical Developments



    
    - Next-generation devices highlighted in upcoming presentations -
    

    OAKLAND, Calif., June 6 /CNW/ -- World Heart Corporation (Nasdaq:   WHRTD,
TSX: WHT), a developer of mechanical circulatory support systems, will be
presenting Levacor(TM) Rotary VAD initial clinical results and other related
development progress at two upcoming clinical and scientific conferences.
    At the American Society of Artificial Internal Organs (ASAIO) Annual
Conference to be held in Chicago from June 7-9th, a slide presentation titled
'First Clinical Experience with the Levacor(TM) Rotary VAD' will be presented
by Dr. James Long, M.D., Ph.D.  This overview will be presented in the session
on 'Ventricular Remodeling after Infarction'.  Dr. Long, cardiothoracic
surgeon at LDS Hospital, Salt Lake City, Utah, a clinical leader in the
mechanical circulatory support field, and member of the Levacor VAD Clinical
Trial Coordinating Committee, assisted in the clinical training and
implantation of the device in Europe starting in March 2006.
    In addition, an overview of the device's development covering 'Design to
Clinical Feasibility' will be presented by Gill Bearnson, Ph.D, WorldHeart's
Chief Engineering Scientist, and specific test results with the magnetic
suspension control system will be presented by James Lee, M.S., WorldHeart's
Director of Engineering.
    There will also be several ASAIO presentations made by WorldHeart's
collaborators on the Pediaflow(TM) pediatric VAD.  These presentations include
an overview of Pediaflow VAD development for infants and small children,
engineering analyses such as computational study of hemodynamics, cannula
design, as well as surface modification and blood compatibility science.  The
technology from the National Institutes of Health funded Pediaflow is
applicable to an adult, Minimally Invasive VAD intended to provide partial
support in earlier-stage heart failure patients.
    Concurrently, at the 4th International Conference on Functional Imaging
and Modeling of the Heart, to be held in Salt Lake City, Utah from June 7-9th,
Pratap Khanwilkar, Ph.D., WorldHeart's Vice President, Rotary Systems and
Business Development, will present an invited talk at the Industrial Session
on 'Imaging and Modeling Techniques in the Development and Clinical Use of the
Levacor VAD'.
    Dr. Khanwilkar remarked that, "We are eager to share the initial clinical
results of the Levacor VAD with a North American clinical and scientific
audience for the first time at ASAIO.  We are also pleased to discuss key
areas of development contributing to the performance of the Levacor VAD."

    
    About the Levacor VAD
    
    The Levacor is a next-generation rotary VAD.  It is the only bearingless,
fully magnetically levitated implantable centrifugal rotary pump with clinical
experience.  An advanced, continuous-flow pump, the Levacor uses magnetic
levitation to fully suspend the spinning rotor, its only moving part, inside a
compact housing.  The proprietary levitation technology employs a unique
arrangement of magnetics expected to provide optimal system simplicity and
reliability.  In contrast to pumps with blood-immersed mechanical or
hydrodynamic bearings, full magnetic levitation eliminates wear within the
pump as well as dependence on blood properties for rotor suspension, and is
expected to provide improved blood compatibility by allowing greater
clearances around the rotor and more idealized flow patterns across a wider
range of operation.  The Levacor VAD has been designed with a high safety
profile and robust range of operation to address the needs of current and
future heart failure patients.

    
    About the Pediaflow VAD
    
    The Pediaflow VAD is designed to provide medium-term (< 1 year)
implantable circulatory support to newborns and infants. The consortium
performing the early design and development is led by the University of
Pittsburgh supported by a 5-year, $4.3 million dollar contract from the
National Heart, Lung and Blood Institute of the National Institutes of Health.
WorldHeart is an integral member of the consortium, as are the Children's
Hospital of Pittsburgh, the University of Pittsburgh Medical Center (UPMC),
the Artificial Heart Program at LDS Hospital in Salt Lake City, Primary
Children's Medical Center in Salt Lake City, LaunchPoint Technologies and
Carnegie-Mellon University.

    
    About WorldHeart
    
    WorldHeart is a developer of mechanical circulatory support systems with
leading next-generation technologies.  The Company is headquartered in
Oakland, California, USA with additional facilities in Salt Lake City, Utah
and The Netherlands. WorldHeart's registered office is Ottawa, Ontario,
Canada.

    Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995
and include statements regarding the Company's expectations with respect to
the Company's future development plans for its next-generation Levacor VAD and
Pediaflow VAD, including the timing and scope of clinical trials, as well as,
other statements that can be identified by the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will," "should,"
"seeks," "plans," "anticipates," or "intends" or the negative of those terms,
or by discussions of strategy or intentions. Investors are cautioned that all
forward-looking statements involve risk and uncertainties, including without
limitation: delays in development, preclinical qualification and regulatory
approvals, with clinical trials; Destination Therapy adoption rate for VADs;
need for additional financing; and other risks detailed in the Company's
filings with the United States Securities and Exchange Commission, including
its Annual Report on Form 10-KSB for the year ended December 31, 2006, as
amended.





For further information:

For further information: Mr. Richard Juelis, +1-510-563-4713, or Ms.
Peggy  Allman, +1-510-563-4721, both of World Heart Corporation; or Mr.
Stephen Laird,  +1-203-341-0214, of Genesis Select Corporation Web Site:
http://www.worldheart.com                  http://www.genesisselect.com

Organization Profile

WORLD HEART CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890